High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.

We assessed the cerebrospinal fluid (CSF) by flow cytometry and cytology in 51 newly diagnosed and 9 treated aggressive B-cell lymphomas at risk for central nervous system (CNS) involvement to examine the utility of flow cytometry, incidence of CSF disease, and clinical surrogates of CNS spread. Multicolor flow cytometry using multiple antibody panels for light chains and B- and T-cell antigens identified neoplastic clones that constituted as little as 0.2% of total CSF lymphocytes. Among 51 newly diagnosed patients, 11 (22%) had occult CSF involvement. All 11 were detected by flow cytometry but only 1 by cytology (P = .002). Among 9 treated patients, CSF involvement was detected by flow cytometry alone in 2 and also by cytology in 1 case. CSF chemistry and cell counts were similar in patients with and without CSF lymphoma. Only the number of extranodal sites was associated with occult CSF lymphoma in newly diagnosed patients by univariate (P = .006) or logistic regression analysis (P = .012). We hypothesize that the biologic phenotype associated with colonization of extranodal sites leads to CNS spread, possibly related to the microenvironment. Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry.

[1]  T. Molina,et al.  Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  T. Molina,et al.  Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.

[3]  M. Stetler-Stevenson Flow cytometry in lymphoma diagnosis and prognosis: useful? , 2003, Best practice & research. Clinical haematology.

[4]  U. Schlegel,et al.  Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature , 2003, Oncology Research and Treatment.

[5]  W. Wilson,et al.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. , 2003, Blood.

[6]  W. Wilson,et al.  Update on the pathogenesis, diagnosis, and therapy of AIDs-related lymphoma , 2003, Current infectious disease reports.

[7]  L. Staudt,et al.  Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. , 2002, Blood.

[8]  R. Braylan,et al.  Flow cytometric analysis of lymphomas and lymphoproliferative disorders. , 2001, Seminars in hematology.

[9]  D. Dorfman,et al.  Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: Increased sensitivity using flow cytometric analysis , 2000, Diagnostic cytopathology.

[10]  M. Ward,et al.  The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. , 1999, Pathology.

[11]  L. Peterson,et al.  Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. , 1998, American journal of clinical pathology.

[12]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[13]  M. Stetler-Stevenson,et al.  Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. , 1996, Cytometry.

[14]  J. Myles,et al.  Review Article Flow Cytometric Immunophenotyping of Non-Hodgkin's Lymphomas and Related Disorders , 1996 .

[15]  L. Skoog,et al.  Diagnosis of lymphoma, leukemia, and metastatic tumor involvement of the cerebrospinal fluid by cytology and immunocytochemistry , 1995, Diagnostic cytopathology.

[16]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[17]  L. Frankel,et al.  Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R C Braylan,et al.  Analysis of Lymphomas by Flow Cytometry Current and Emerging Strategies , 1993, Annals of the New York Academy of Sciences.

[19]  P. Wen,et al.  Deceptively normal ventricular fluid in lymphomatous meningitis. , 1993, Archives of internal medicine.

[20]  T. Siegal,et al.  CNS involvement by non-Hodgkin's lymphoma. Response to a standard therapeutic protocol. , 1984, Archives of neurology.

[21]  F. Cabanillas,et al.  Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. , 1979, Blood.

[22]  M. Melamed,et al.  Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology , 2011, Neurology.

[23]  E. Jaffe,et al.  Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. , 1979, The American journal of medicine.